97058 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
TAG72 TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF TAG72-POSITIVE TUMORS
#2CD33 TARGETED IMMUNOTHERAPIES
#3HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
#4NOVEL COMPOSITION COMPRISING ANTIBODIES
#5COMBINATION OF NY-ESO-1 SPECIFIC T CELL RECEPTORS AND CHIMERIC CO-STIMULATORY RECEPTORS
#6ANTI-TNF-ALPHA POLYPEPTIDE COMPOSITION AND USE THEREOF
#7HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
#8HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
#9IMMUNOMODULATORY FUSION PROTEINS AND RELATED METHODS
#10SMALL MOLECULE ADAPTER REGULATED, TARGET SPECIFIC CHIMERIC ANTIGEN RECEPTOR BEARING T CELLS (SMART CARS)
#11Fc VARIANTS WITH ALTERED BINDING TO FcRn
#12TREATMENT OF CANCER USING A CD33 CHIMERIC ANTIGEN RECEPTOR
#13ARTIFICIAL IMMUNE RECEPTORS
#14EXOSOMES FOR IMMUNO-ONCOLOGY AND ANTI-INFLAMMATORY THERAPY
#15HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
#16Fc VARIANTS WITH ALTERED BINDING TO FcRn
#17PHARMACEUTICAL FORMULATIONS AND METHODS OF MAKING THE SAME
#18COMBINATION OF A CELL THERAPY AND A GAMMA SECRETASE INHIBITOR
#19CHIMERIC ADIPONECTIN POLYPEPTIDES, EXTRACELLULAR VESICLE COMPRISING THE SAME, AND USES THEREOF
#20APRIL AND BAFF INHIBITORY IMMUNOMODULATORY PROTEINS AND METHODS OF USE THEREOF
#21APRIL AND BAFF INHIBITORY IMMUNOMODULATORY PROTEINS AND METHODS OF USE THEREOF
#22HUMAN MESOTHELIN CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
#23SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
#24S309 CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE
#25April and BAFF inhibitory immunomodulatory proteins and methods of use thereof
#26HEPATITIS B VIRUS ANTIVIRUS (HBV-ANTIVIRUS) COMPOSITIONS AND METHODS OF USE
#27TPO MIMETIC FUSION PROTEINS AND METHODS OF USE
#28METHOD AND COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY
#29VECTORIZED TNF-ALPHA ANTAGONISTS FOR OCULAR INDICATIONS
#30Engineered Expression of Cell Surface and Secreted Sialidase by CAR T Cells for Increased Efficacy in Solid Tumors
#31ANTIBODY AGAINST GLYPICAN-3 AND APPLICATION THEREOF
#32Fc VARIANTS WITH ALTERED BINDING TO FcRn
#33METHOD FOR PURIFYING PROTEINS
#34TRUNCATED TACI POLYPEPTIDE AND FUSION PROTEIN AND USE THEREOF
#35HUMAN MESOTHELIN CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
#36COMPOUNDS AND METHODS FOR TREATING PAIN
#37Fc VARIANTS WITH ALTERED BINDING TO FcRn
#38APRIL AND BAFF INHIBITORY IMMUNOMODULATORY PROTEINS AND METHODS OF USE THEREOF
#39CHIMERIC RECEPTORS TARGETING MUC16 AND USES THEREOF
#40CHIMERIC RECEPTOR PROTEINS AND USES THEREOF
#41COMPOSITIONS AND METHODS OF TREATING CANCER WITH CHIMERIC ANTIGEN RECEPTORS
#42COMPOSITION FOR CONTROLLED RELEASE OF THERAPEUTIC AGENTS
#43CELL CULTURE METHOD
#44MODIFIED IMMUNE EFFECTOR CELL AND USE THEREOF
#45AN INTERLEUKIN-1 RECEPTOR ANTAGONIST AND A FUSION PROTEIN CONTAINING THE SAME
#46CHIMERIC ANTIGEN RECEPTOR
#47EXOSOMES FOR IMMUNO-ONCOLOGY AND ANTI-INFLAMMATORY THERAPY
#48ENGINEERED EXTRACELLULAR VESICLES DISPLAYING ENHANCED PHARMACOKINETICS
#49COMPOSITIONS AND USES OF CD45 TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS
#50TREATING RHEUMATOID ARTHRITIS
#51STRENGTHENED RECEPTOR FOR IMPROVING IMMUNE CELL FUNCTION
#52Exosome for stimulating T cell and pharmaceutical use thereof
#53T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF
#54CHIMERIC MOLECULES PROVIDING TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY
#55MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF
#56ANTIBODIES SPECIFIC FOR CD22 AND USES THEREOF
#57CHIMERIC ANTIGEN RECEPTOR SPECIFICALLY BINDING TO CD138, IMMUNE CELL EXPRESSING SAME, AND ANTICANCER USE THEREOF
#58PROCESS FOR PRODUCING DONOR-BATCHED CELLS EXPRESSING A RECOMBINANT RECEPTOR
#59Chimeric antigen receptors targeting FLT3
#60Elimination of BCMA-positive malignancies by CAR expressing NK cells
#61SMALL MOLECULE ADAPTER REGULATED, TARGET SPECIFIC CHIMERIC ANTIGEN RECEPTOR BEARING T CELLS (SMART CARS)
#62POLYMERIC NANOPARTICLES PROVIDING NUCLEIC ACIDS ENCODING TNF-a
#63CHIMERIC STIMULATORY RECEPTORS AND METHODS OF USE IN T CELL ACTIVATION AND DIFFERENTIATION
#64COMPOSITIONS AND METHODS OF STIMULATING AND EXPANDING T CELLS
#65COMPOSITIONS AND METHODS FOR USE IN IMMUNOTHERAPY
#66Methods of treatment of arthritis and/or psoriasis with pharmaceutical formulations of etanercept
#67MODULATION OF IMMUNE RESPONSE USING BTLA AGONIST ANTIBODIES
#68TRANSGENE GENETIC TAGS AND METHODS OF USE
#69DEFINED COMPOSITION GENE MODIFIED T-CELL PRODUCTS
#70CHIMERIC ANTIGEN RECEPTOR TARGETING CLL1 AND USE THEREOF
#71CHIMERIC COSTIMULATORY RECEPTORS AND METHODS AND USES THEREOF
#72GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC TNFR2
#73DCR3 VARIANT
#74SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
#75CD33 TARGETED IMMUNOTHERAPIES
#76REDIRECTING DEATH-INDUCING SIGNAL COMPLEX (DISC) BY MODIFYING DEATH RECEPTOR AGONIST TO INDUCE CELL DEATH FOR CANCER TREATMENT
#77CHIMERIC PROTEINS IN AUTOIMMUNITY
#78Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
#79CHIMERIC CYTOKINE RECEPTOR CAPABLE OF IMMUNE SIGNAL CONVERSION, IMMUNE CELLS EXPRESSING SAME, AND ANTI-CANCER USE THEREOF
#80NOVEL COMPOSITION COMPRISING ANTIBODIES
#81Fc VARIANTS WITH ALTERED BINDING TO FcRn
#82HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE
#83DIMER IMMUNOADHESIN, PHARMACEUTICAL COMPOSTION AND USE THEREOF
#84ANTI-L1CAM ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND CHIMERIC ANTIGEN RECEPTOR COMPRISING SAME
#85ANTI-CD33 IMMUNE CELL CANCER THERAPY
#86ENHANCEMENT OF POLYPEPTIDES AND CHIMERIC ANTIGEN RECEPTORS VIA HINGE DOMAINS
#87CELLS EXPRESSING A CHIMERIC RECEPTOR FROM A MODIFIED CD247 LOCUS, RELATED POLYNUCLEOTIDES AND METHODS
#88COMPOSITION FOR CONTROLLED RELEASE OF THERAPEUTIC AGENTS
#89S309 chimeric antigen receptors and methods of use
#90Removal of leaked affinity purification ligand
#91BAFF-R/CD19 TARGETED CHIMERIC ANTIGEN RECEPTOR-MODIFIED T CELLS AND USE THEREOF
#92Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
#93Drug regulated transgene expression
#94Anti-Human Transferrin Receptor Antibody Permeating Blood-Brain Barrier
#95CR3022 chimeric antigen receptors and methods of use
#96DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES
#97APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof
#98METHOD AND COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY
#99APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof
#100Soluble TNF Receptors and Their Use in Treatment of Disease
#101Compounds and methods for treating pain
#102Compositions and methods of treating cancer with chimeric antigen receptors
#103Arginine-free TNFR:FC-fusion polypeptide compositions
#104TAG72 targeted chimeric antigen receptor modified T cells for treatment of TAG72-positive tumors
#105HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
#106CHIMERIC RECEPTORS TO STEAP1 AND METHODS OF USE THEREOF
#107Fc variants with altered binding to FcRn
#108BCMA CAR-T cells with enhanced activities
#109Affinity purification of engineered extracellular vesicles
#110SINGLE CHAIN Fc FUSION PROTEINS
#111METHODS FOR MAKING STABLE PROTEIN COMPOSITIONS
#112TREATMENT OF CANCER USING A CD33 CHIMERIC ANTIGEN RECEPTOR
#113Production of engineered T-cells by sleeping beauty transposon coupled with methotrexate selection
#114Fc VARIANTS WITH ALTERED BINDING TO FcRn
#115METHOD AND COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY
#116Serpin fusion polypeptides and methods of use thereof
#117COMPOUNDS AND METHODS FOR TREATING PAIN
#118C-TERMINALLY FUSED TNF FAMILY LIGAND TRIMER-CONTAINING ANTIGEN BINDING MOLECULES
#119ETANERCEPT FORMULATIONS EXHIBITING MARKED REDUCTION IN SUB-VISIBLE PARTICLES
#120Transgene genetic tags and methods of use
#121Serpin fusion polypeptides and methods of use thereof
#122Human mesothelin chimeric antigen receptors and uses thereof
#123Exosomes for immuno-oncology and anti-inflammatory therapy
#124ETANERCEPT FORMULATIONS STABILIZED WITH XYLITOL
#125CO-STIMULATORY DOMAINS FOR USE IN GENETICALLY-MODIFIED CELLS
#126Engineered Expression of Cell Surface and Secreted Sialidase by CAR T Cells for Increased Efficacy in Solid Tumors
#127Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same
#128Combination of a cell therapy and a gamma secretase inhibitor
#129SELECTIVE TNFR1 ANTAGONIST PEPTIDE SN10 AND APPLICATION THEREOF IN INFLAMMATORY BOWEL DISEASE
#130Fc VARIANTS WITH ALTERED BINDING TO FcRn
#131Fc VARIANTS WITH ALTERED BINDING TO FcRn
#132HUMANIZED BCMA-CAR-T CELLS
#133Methods for purifying proteins
#134BISPECIFIC FUSION PROTEIN FOR IL-17 AND TNF-alpha
#135Compounds and methods for treating pain
#136Serpin fusion polypeptides and methods of use thereof
#137SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
#138METHODS OF MODULATING IMMUNE RESPONSES USING BCMA POLYPEPTIDE
#139Inhibitors of LTβR-NFκB signaling pathways for treating inflammation and cancer
#140Method and compositions for cellular immunotherapy
#141Exosome for stimulating T cell and pharmaceutical use thereof
#142ANTI-TNF-ALPHA POLYPEPTIDE COMPOSITION AND USE THEREOF
#143Co-stimulatory domains for use in genetically-modified cells
#144CHIMERIC RECEPTORS, BIOSENSOR HOST CELLS AND METHODS/USES THEREOF
#145TISSUE-BASED BIOLOGICS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISORDERS
#146Polymeric nanoparticles providing nucleic acids encoding TNF-α
#147Soluble TNF Receptors and Their Use in Treatment of Disease
#148POLYPEPTIDES AND USES THEREOF AS A DRUG FOR TREATMENT OF AUTOIMMUNE DISORDERS
#149Composition for controlled release of therapeutic agents
#150Method of reducing formation of etanercept aggregates or fragments
#151Stable aqueous etanercept composition
#152Method of reducing formation of etanercept aggregates or fragments
#153Stable aqueous etanercept composition
#154Method of Reducing Formation of Etanercept Aggregates or Fragments
#155USE OF ANTIBODY-COUPLED T CELL RECEPTOR (ACTR) WITH MULTIPLE ANTI-CANCER ANTIBODIES IN CANCER TREATMENT
#156Drug regulated transgene expression
#157Antigen binding molecules comprising a TNF family ligand trimer and a Tenascin binding moiety
#158Cell-associated secretion-enhancing fusion proteins
#159Co-stimulatory domains for use in genetically-modified cells
#160Etanercept formulations stabilized with amino acids
#161Exosomes for immuno-oncology and anti-inflammatory therapy
#162Etanercept formulations stabilized with xylitol
#163IMMORTALIZED CAR-T CELLS GENETICALLY MODIFIED TO ELMINATE T-CELL RECEPTOR AND BETA 2-MICROGLOBULIN EXPRESSION
#164Anti-BCMA chimeric antigen receptor
#165COMPOSITIONS AND METHODS FOR TISSUE REPAIR
#166T-cell modulatory multimeric polypeptides and methods of use thereof
#167Removal of leaked affinity purification ligand
#168Antibody against glypican-3 and application thereof
#169Pharmaceutical formulations and methods of making the same
#170Epitope for switching to T2 cell and use thereof
#171Epitope for switching to T1 cell and use thereof
#172Method of manufacturing a protein by perfusion in media with a low amino acid concentration
#173Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same
#174CHIMERIC POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME, CELLS EXPRESSING SAME AND METHODS OF PRODUCING SAME
#175Single chain Fc fusion proteins
#176Kit for immunological detection of TNF-alpha, sTNFR1 and IL-8 in prostate cancer
#177Methods of modulating immune responses using BCMA polypeptide
#178Tumor necrosis factor 1B (TNF-1B) mutants and methods of use thereof to screen for candidate therapeutic compounds
#179Core constructs and their uses in configuring pharmaceutical molecules
#180Methods for Optimizing CATS Immunotherapeutics into Humanized Derivatives with Reduced Autoreactivity, Reduced Toxicity and Enhanced Long-Term Efficacy
#181Pharmaceutical formulations and methods of making the same
#182Method for in vivo expansion of T regulatory cells
#183Compounds and methods for treating pain
#184THERAPEUTIC AND DIAGNOSTIC AGENTS
#185Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
#186Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
#187Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity.
#188Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
#189Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
#190ALBUMIN FUSION PROTEINS
#191Method and compositions for cellular immunotherapy
#192Etanercept formulations stabilized with combinations of sugars and polyols
#193Cells producing glycoproteins having altered N- and O-glycosylation patterns and methods and use thereof
#194Serpin fusion polypeptides and methods of use thereof
#195Anti-human transferrin receptor antibody permeating blood-brain barrier
#196Epitope for switching to T17 cell and use thereof
#197Treatment of X-linked hypohidrotic ectodermal dysplasia with a fusion EDA1 protein
#198Modulation of immune response using BTLA agonist antibodies
#199TUMOUR NECROSIS FACTOR RECEPTOR FUSION PROTEINS AND METHODS OF USING THE SAME
#200Etanercept formulations stabilized with metal ions
#201Anhydrous hydrogel composition and delivery system
#202Eukaryotic expression vectors comprising regulatory elements of the globin gene clusters
#203ANTI-TNF-ALPHA POLYPEPTIDE COMPOSITION AND USE THEREOF
#204Treatment of cancer using a CD33 chimeric antigen receptor
#205Etanercept formulations stabilized with xylitol
#206Method of treating cancer by administering tumor necrosis factor receptor ligand superfamily (TNFRSF) single-chain polypeptides
#207Method and compositions for cellular immunotherapy
#208Method for preparing TNFR-Fc fusion protein containing target content of impurities
#209Liquid pharmaceutical composition of etanercept with lysine and proline
#210METHOD OF USING A PEPTIDE LIBRARY
#211Transgene genetic tags and methods of use
#212Compositions and methods of stimulating and expanding T cells
#213COMPOSITIONS, METHODS, AND COMPUTER SYSTEMS RELATED TO MAKING AND ADMINISTERING MODIFIED T CELLS
#214Compositions and methods for regulating glucose metabolism
#215Method for treating melanoma
#216Drug regulated transgene expression
#217ALBUMIN FUSION PROTEINS
#218Fusion protein inhibiting TACI-BAFF complex formation and preparation method therefor and use thereof
#219Pharmaceuticals in joint-linker configurations for treating pathological blood clots
#220Method for treating CD40-mediated diseases
#221USE OF CATION-EXCHANGE CHROMATOGRAPHY IN THE FLOW-THROUGH MODE TO ENRICH POST-TRANSLATIONAL MODIFICATIONS
#222Etanercept formulations stabilized with xylitol
#223Human mesothelin chimeric antigen receptors and uses thereof
#224Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same
#225Methods for treating cancer
#226Molecular constructs with targeting and effector moieties
#227Peptide core-based multi-arm linkers
#228Molecular constructs for treating tumors
#229Etanercept formulations stabilized with combinations of sugars and polyols
#230Method of improving the pharmacokinetic profile of a therapeutic polypeptide and the use thereof
#231Treatment of X-linked hypohidrotic ectodermal dysplasia with a fusion EDA1 protein
#232Use of osteoprotegerin (OPG) to increase human pancreatic beta cell survival and proliferation
#233ALBUMIN FUSION PROTEINS
#234Correctly folded etanercept composition
#235Treatment of cancer using a CD33 chimeric antigen receptor
#236Compositions and Methods for Controlled Release of Agents
#237Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor
#238Novel Epitope for Switching to TH2 Cell and Use Thereof
#239Hybrid immunoglobulin containing non-peptidyl linkage
#240MODIFIED FC FUSION PROTEINS
#241REMOVAL OF LEAKED AFFINITY PURIFICATION LIGAND
#242Quantification of misfolded TNFR2:Fc
#243TNF alpha INHIBITOR POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME, CELLS EXPRESSING SAME AND METHODS OF PRODUCING SAME
#244Methods for treating or reducing liver diseases by administering oral composition comprising TNF receptor fusion proteins
#245Method and compositions for cellular immunotherapy
#246HUMANIZED TRANSGENIC SINGLE NUCLEOTIDE POLYMORPHISM ANIMAL SYSTEMS
#247Liquid formulations for TNFR:Fc fusion proteins
#248Compounds and methods for treating pain
#249Method of manufacturing a protein by perfusion in media with a low amino acid concentration
#250Stable aqueous formulations of etanercept
#251Fc variants with altered binding to FcRn
#252COMPOSITIONS AND METHODS FOR INCREASING SERUM HALF-LIFE
#253Soluble TNF Receptors and Their Use in Treatment of Disease
#254Serpin fusion polypeptides and methods of use thereof
#255WAP domain fusion polypeptides and methods of use thereof
#256Methods of treating autoimmune diseases using a B-cell maturation antigen (BCMA)
#257Etanercept formulations exhibiting marked reduction in sub-visible particles
#258Uses of modified human tumor necrosis factor receptor-1 polypeptide
#259Serpin fusion polypeptides and methods of use thereof
#260Cancer treatment and monitoring methods using OX40 agonists
#261Methods for treatment of brain injury utilizing biologics
#262HYBRID CONSTANT REGIONS
#263Protein layers and their use in electron microscopy
#264Tumour necrosis factor receptor fusion proteins and methods of using the same
#265Methods for reducing mannosyltransferase activity in lower eukaryotes
#266Treatment of X-linked hypohidrotic ectodermal dysplasia with ectodysplasin A agonist
#267Anhydrous hydrogel composition and delivery system
#268COMPOSITIONS AND METHODS FOR INCREASING SERUM HALF-LIFE
#269Fusion protein comprising circularly permuted form of trail/Apo2L, coding gene and use thereof
#270Methods for preparing an active TNFR-Fc fusion protein
#271Compositions and methods for regulating glucose metabolism
#272Perfusion method for manufacturing etanercept
#273Methods of preparing lyophilized spherical-shaped pellets of biological materials
#274ORAL COMPOSITION COMPRISING A TNF ANTAGONIST AND USE THEREOF
#275Arginine-free TNFR:Fc-fusion polypeptide compositions and methods of use
#276Peptides and related molecules that bind to TALL-1
#277Stem cell administration to reduce TNF-α level in CSF of an autism spectrum disorder or pervasive development disorder patient
#278RECEPTOR ACTIVATOR OF NF-kappaB
#279Stable pharmaceutical liquid formulations of the fusion protein TNFR:Fc
#280METHOD OF INHIBITING OSTEOCLAST ACTIVITY
#281PURIFICATION OF CHIMERIC PROTEIN
#282Synthetic peptide that induces expression of TNF receptor 2 and use thereof
#283Transgenic pig expressing sTNFR1-Fc genes and the uses thereof
#284Treatment with factor ix-albumin fusion protein
#285Methods for use of a specific anti-angiogenic adenoviral agent
#286Treatment with factor VII-albumin fusion protein
#287Serpin fusion polypeptides and methods of purification thereof
#288Peptide library
#289Albumin Fusion Proteins
#290Modified human tumor necrosis factor receptor-I polypeptide or fragment thereof, and method for preparing same
#291Expression vector and methods of producing high levels of proteins
#292Methods for treatment of brain injury utilizing biologics
#293ErbB interface peptidomimetics and methods of use thereof
#294Heterodimeric human IgG1 polypeptides with isoelectric point modifications
#295Etanercept formulations stabilized with metal ions
#296Etanercept formulations stabilized with amino acids
#297Soluble tumor necrosis factor receptor (sTNF-R) used as a targeting agent to treat arthritis and other diseases
#298METHOD OF INHIBITING OSTEOCLAST ACTIVITY
#299Etanercept formulations stabilized with xylitol
#300Compositions and methods for increasing serum half-life